Asabys Partners

Investor type Venture Capital
Founders Clara Campas Josep L.l. Sanfeliu

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 13
Average round size
info
The average size of a deal this fund participated in
$13M
Portfolio companies 10
Rounds per year 4.33
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Key employees 3

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Medical
  • Life Science
Summary

In 2018 was created Asabys Partners, which is appeared as VC. The fund was located in Europe if to be more exact in Spain. The leading representative office of defined VC is situated in the Barcelona.

Among the most popular portfolio startups of the fund, we may highlight Psious. For fund there is a match between the location of its establishment and the land of its numerous investments - Spain. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Wearables, Health Diagnostics.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Asabys Partners, startups are often financed by Atlantic Labs, Rothenberg Ventures, Founders Factory. The meaningful sponsors for the fund in investment in the same round are Sabadell Venture Capital, Ysios Capital, Omega Funds.

The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. Deals in the range of 5 - 10 millions dollars are the general things for fund. Considering the real fund results, this VC is 80 percentage points more often commits exit comparing to other organizations.

The current fund was established by Clara Campas, Josep L.l. Sanfeliu.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Asabys Partners:
Typical Co-investors
Asabys Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Asabys Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Business Investors Group (BiG) Cheshire, Chester, United Kingdom
Cornerstone Capital Beijing, China, Haidian
Crede CapitalGroup California, Los Angeles, United States
DCP Capital Beijing, Beijing, China
Dongxin Ziben China, Jiangsu, Nanjing
Florida Silicon Partners Florida, Naples, United States
G2 Momentum Capital Distrito Federal, Mexico, Mexico City
Grauer Brothers Capital Atherton, California, United States
INGENIUM Sardegna Fund Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Intango Ventures Israel, Tel Aviv, Tel Aviv District
Inundata New York, New York, United States
Inventive Innovations -
Naspers Foundry -
New World Strategic Investment China, Shanghai
Simon Ventures New York, New York, United States
Sumitomo Mitsui Financial Group Chiyoda, Japan
Techstars Retail Accelerator Minneapolis, Minnesota, United States
W.IN.G -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

INBRAIN Neuroelectronics

Biotechnology
Consumer Electronics
Medical Device
$16M26 Mar 2021 Barcelona, Catalonia, Spain

Medlumics

Biotechnology
CRM
Health Care
Hospital
Information Technology
Medical Device
Robotics
$21M10 Feb 2021 Spain, Community of Madrid

Koa Health

Health Care
Medical
Medical Device
Natural Language Processing
$35M09 Feb 2021 Spain, Catalonia

SidekickHealth

Health Care
Health Diagnostics
Medical
Mobile
$20M28 Oct 2020 Västra Götaland County

Splice Bio

Biotechnology
Life Science
Medical
Pharmaceutical
15 Sep 2020 Spain, Catalonia

Origo Biopharma

Biotechnology
Pharmaceutical
$2M07 Jul 2020 -

Ona Therapeutics

Biotechnology
Health Care
Life Science
$35M16 Jun 2020 Spain, Catalonia

INBRAIN Neuroelectronics

Biotechnology
Consumer Electronics
Medical Device
$1M11 Jun 2020 Spain, Catalonia

Anaconda BioMed

Health Care
Hospital
Medical
Medical Device
$23M04 Dec 2019 Spain, Catalonia
News
INBRAIN Neuroelectronics Secures $17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface

– INBRAIN Neuroelectronics S.L. announced $16.8m in Series A funding for its disruptive system for treating epilepsy and Parkinson’s disease.
– The investment was co-led by Asabys Partners and Alta Life Sciences and joined by Vsquared Ventures and TruVenturo GmbH.
– The funding will be used to advance INBRAIN’s first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices.
– INBRAIN’s technology harnesses the power of graphene, a two-dimensional material first isolated in 2004 made of a lattice of carbon atoms only one atom thick.

MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

– MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round.
– MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
– This round was led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II.
– MedLumics is now ready to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Asabys Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: